CY1119084T1 - Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης - Google Patents

Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης

Info

Publication number
CY1119084T1
CY1119084T1 CY20171100592T CY171100592T CY1119084T1 CY 1119084 T1 CY1119084 T1 CY 1119084T1 CY 20171100592 T CY20171100592 T CY 20171100592T CY 171100592 T CY171100592 T CY 171100592T CY 1119084 T1 CY1119084 T1 CY 1119084T1
Authority
CY
Cyprus
Prior art keywords
substituted tricyclic
compounds
disclosed
tricyclic benzimidazoles
inhibitors
Prior art date
Application number
CY20171100592T
Other languages
English (en)
Inventor
Tomasz Rzymski
Adrian Zarebski
Agnieszka Dreas
Karolina Osowska
Katarzyna Kucwaj
Joanna Fogt
Marek Cholody
Michal Galezowski
Wojciech Czardybon
Raymond Horvath
Katarzyna Wiklik
Mariusz Milik
Krzysztof Brzózka
Original Assignee
Selvita S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita S.A. filed Critical Selvita S.A.
Publication of CY1119084T1 publication Critical patent/CY1119084T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Εδώ αποκαλύπτονται ενώσεις υποκατεστημένων τρικυκλικών βενζιμιδαζολίων όπως ορίζονται εδώ στον τύπο (I) ή φαρμακευτικώς αποδεκτά άλατα αυτών. Οι ενώσεις της εφεύρεσης αναστέλλουν εκλεκτικώς την CDK8 και είναι συνεπώς χρήσιμες για τη θεραπεία νόσων που σχετίζονται με αυτή την κινάση, ειδικότερα ορθοκολικών και μελανωματικών καρκίνων και άλλων στερεών και αιματολογικών κακοηθειών, αυτοάνοσων νόσων και φλεγμονωδών νόσων. Επίσης αποκαλύπτονται διεργασίες για την παρασκευή αυτών των ενώσεων.
CY20171100592T 2012-11-08 2017-06-06 Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης CY1119084T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1220157.0A GB201220157D0 (en) 2012-11-08 2012-11-08 Substitute tricyclic benzimidazoles as kinase inhibitors
PCT/EP2013/073311 WO2014072435A1 (en) 2012-11-08 2013-11-07 Substituted tricyclic benzimidazoles as kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1119084T1 true CY1119084T1 (el) 2018-01-10

Family

ID=47470315

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100592T CY1119084T1 (el) 2012-11-08 2017-06-06 Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης

Country Status (23)

Country Link
US (1) US9745299B2 (el)
EP (1) EP2917217B1 (el)
JP (1) JP6101812B2 (el)
KR (1) KR101812390B1 (el)
CN (1) CN104903321B (el)
AU (1) AU2013343550B2 (el)
BR (1) BR112015010019B1 (el)
CA (1) CA2890643C (el)
CY (1) CY1119084T1 (el)
DK (1) DK2917217T3 (el)
ES (1) ES2628046T3 (el)
GB (1) GB201220157D0 (el)
HR (1) HRP20170802T1 (el)
HU (1) HUE033485T2 (el)
IL (1) IL238693A0 (el)
LT (1) LT2917217T (el)
MX (1) MX363609B (el)
PL (1) PL2917217T3 (el)
PT (1) PT2917217T (el)
RS (1) RS56056B1 (el)
SI (1) SI2917217T1 (el)
SM (1) SMT201700291T1 (el)
WO (1) WO2014072435A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3133075B1 (en) 2014-04-18 2020-12-30 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
BR112018008931A8 (pt) * 2015-11-03 2019-02-26 Lu License Ab ?compostos para tratamento de distúrbios hipoproliferativos?
JP7142846B2 (ja) 2017-01-30 2022-09-28 国立大学法人京都大学 新規化合物及び制御性ｔ細胞の製造方法
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
WO2018186366A1 (ja) * 2017-04-03 2018-10-11 京都薬品工業株式会社 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
CN111163775B (zh) 2017-10-02 2023-07-11 勃林格殷格翰国际有限公司 作为cdk8/cdk19抑制剂的新型[1,6]萘啶化合物和衍生物
AU2019326633B2 (en) * 2018-08-24 2022-09-08 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
CN113631535B (zh) * 2019-03-11 2024-04-12 协同医药发展有限公司 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN116391028A (zh) 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202246489A (zh) 2021-02-09 2022-12-01 日商千紙鶴治療公司 成熟化劑
WO2022204534A1 (en) * 2021-03-25 2022-09-29 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
EP4410965A4 (en) 2021-09-27 2025-09-24 Univ Kyoto T LYMPHOCYTE PRODUCTION PROCESS
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202330911A (zh) 2021-11-24 2023-08-01 日商雷格細胞股份有限公司 人類誘導性控制性ｔ細胞及其製作方法
KR20240130083A (ko) 2021-11-24 2024-08-28 레그셀 가부시키가이샤 T세포 관련 질환을 치료 또는 예방하기 위한 의약 조성물
EP4497822A4 (en) 2022-03-23 2026-03-18 Univ Kyoto PROCESS FOR THE PRODUCTION OF REGULATORY T LYMPHOCYTES
IL315122A (en) 2022-04-25 2024-10-01 Orizuru Therapeutics Inc Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
CN119546748A (zh) 2022-07-14 2025-02-28 千纸鹤治疗公司 细胞移植用纤维蛋白凝胶片
CN120112629A (zh) 2022-09-26 2025-06-06 国立大学法人京都大学 T细胞产生方法
EP4596684A1 (en) 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)
US20260232799A1 (en) 2023-02-08 2026-08-13 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing pemphigus
CN121057812A (zh) 2023-03-29 2025-12-02 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法以及用于治疗或预防t细胞相关疾病的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2899757B2 (ja) 1989-06-26 1999-06-02 持田製薬株式会社 ジヒドロイミダゾキノリノンオキシムスルホン酸誘導体
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
HRP20030081A2 (en) * 2000-08-08 2005-02-28 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
AU2002358650A1 (en) 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AU2003240742A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
MX2008001152A (es) * 2005-08-05 2008-04-02 Astrazeneca Ab Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico.
AU2006296386A1 (en) * 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
US8653089B2 (en) * 2011-02-09 2014-02-18 F. Hoffmann-La Roche Ag Heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
EP2917217B1 (en) 2017-03-08
EP2917217A1 (en) 2015-09-16
IL238693A0 (en) 2015-06-30
CA2890643A1 (en) 2014-05-15
PT2917217T (pt) 2017-06-07
CN104903321B (zh) 2017-10-24
US20150274726A1 (en) 2015-10-01
ES2628046T3 (es) 2017-08-01
BR112015010019A2 (pt) 2017-07-11
BR112015010019A8 (pt) 2019-09-17
SMT201700291T1 (it) 2017-07-18
US9745299B2 (en) 2017-08-29
KR101812390B1 (ko) 2017-12-26
RS56056B1 (sr) 2017-09-29
BR112015010019B1 (pt) 2022-08-09
PL2917217T3 (pl) 2017-10-31
JP2016503408A (ja) 2016-02-04
CA2890643C (en) 2018-05-22
AU2013343550A1 (en) 2015-05-14
WO2014072435A1 (en) 2014-05-15
MX363609B (es) 2019-03-28
CN104903321A (zh) 2015-09-09
HRP20170802T1 (hr) 2017-08-11
SI2917217T1 (sl) 2017-08-31
DK2917217T3 (en) 2017-06-19
HUE033485T2 (en) 2017-12-28
GB201220157D0 (en) 2012-12-26
AU2013343550B2 (en) 2016-09-22
KR20150091074A (ko) 2015-08-07
MX2015005772A (es) 2015-11-18
LT2917217T (lt) 2017-07-25
JP6101812B2 (ja) 2017-03-22

Similar Documents

Publication Publication Date Title
CY1125110T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
MX363609B (es) Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.
CY1123626T1 (el) Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1124793T1 (el) Ακρυλαμιδια πυρρολο[2,3-d]πυριμιδινυλιου, πυρρολo[2,3-β]πυραζινυλιου και πυρρολο[2,3-d]πυριδινυλιου
CY1122611T1 (el) Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης
CY1125127T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CY1120534T1 (el) Μακροκυκλικοι αναστολεις παραγοντα χια συμπυκνωμενοι με ετεροκυκλους
MX390537B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
MX390348B (es) Compuestos de benzimidazol como inhibidores de c-kit
CY1122920T1 (el) ΑΛΑΤΑ ΠΑΡΑΓΩΓΩΝ 2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ-8-ΥΔΡΟΞΥΚΙΝΟΛΙΝ-2(1Η)-ΟΝΗΣ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΕΙΣ ΤΟΣΟ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΩΝ ΥΠΟΔΟΧΕΩΝ ΟΣΟ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΩΝ ΥΠΟΔΟΧΕΩΝ
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
CY1118874T1 (el) Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1119356T1 (el) Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης
GT201300236A (es) Derivados de pirrolo (2,3-d) pirimidina como inhibidores de quinasa relacionados con tropomiosina
CY1118004T1 (el) Αναστολεις cdk
CY1119842T1 (el) Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv
MX376869B (es) Metodos utiles en la sintesis de analogos de halicondrina b.
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις